Reporting directly to the Vice President, USFMO Commercialization, this leader has accountability as the national Field Medical lead for the CELMoDs (Cereblon E3 Ligase Modulator) portfolio, driving Field Medical excellence and an externally focused, patient-centered strategy across all assigned assets, tumor types, and lines of therapy - from early clinical development through post-approval commercialization and lifecycle management. The Executive National Director sits at the intersection of field execution and enterprise medical strategy - setting clear and challenging goals for a high-performing, insight-generating organization, serving as the primary voice of CELMoDs field medical perspective into the broader US Medical Oncology strategy, and representing US Field Medical Oncology in partnership with Global Medical Oncology Home Office, US Commercialization, and Clinical Development.